In today’s briefing:
- Symbio Pharmaceuticals (4582 JP): Full-year FY12/24 flash update
- Novartis: Spinning Off Sandoz—Will a Focused Strategy Pay Off?
- Astellas Pharma (4503 JP): 9MFY25 Result- Strategic Brands Strong; Margins Expand; Guidance Raised
- IDEXX Laboratories: Executing International Expansion To Capitalize On Its Competitive Edge Across Global Veterinary Markets!
- LGMK: New Products, New Distribution Channels, New Agreements
- Shionogi & Co (4507 JP): 9MFY25 Revenue Flat; Insomnia Drug Launched; NDA Submission in Japan
- Tsumura & Co (4540 JP): Q3 FY03/25 flash update
- Charm Care Corp (6062 JP): 1H FY06/25 flash update
- DYAI: Looking Toward Product Revenues
Symbio Pharmaceuticals (4582 JP): Full-year FY12/24 flash update
- Sales decreased by 56.1% YoY to JPY2.5bn, with a gross profit of JPY1.9bn and a gross margin of 76.4%.
- Operating loss increased to JPY3.9bn in FY12/24, with SG&A expenses at JPY5.8bn, including R&D expenses of JPY3.4bn.
- FY12/25 forecast: Sales at JPY1.9bn, operating loss at JPY4.3bn, with total SG&A expenses projected at JPY5.6bn.
Novartis: Spinning Off Sandoz—Will a Focused Strategy Pay Off?
- Novartis reported strong financial results for both the fourth quarter and full year of 2024, marking one of the most robust performances in its history.
- The company recorded a 16% increase in sales in the fourth quarter and a 29% rise in core operating income, both in constant currency.
- For the full year, sales grew 12%, while core operating income expanded by 22%, with an operating margin reaching 38.7%.
Astellas Pharma (4503 JP): 9MFY25 Result- Strategic Brands Strong; Margins Expand; Guidance Raised
- Astellas Pharma (4503 JP) reported a 22% YoY (6% from favourable Fx rates) revenue growth to ¥1,453B in 9MFY25. The U.S. market continue to be key, contributing 46% of revenue.
- Operating profit rose 44% YoY to ¥297.5B, with operating margin expanding 310bps to 20.5%. Core profit increased 35% YoY to ¥223B, with margins improving 150bps to 15.4% in 9MFY25.
- Guidance revised upward, with revenue now expected at ¥1,900B on robust XTANDI performance and favorable forex movement.
IDEXX Laboratories: Executing International Expansion To Capitalize On Its Competitive Edge Across Global Veterinary Markets!
- IDEXX Laboratories, a global leader in veterinary diagnostics, software, and water quality products, closed out 2024 with a solid performance, surpassing expectations and setting a strong foundation for 2025.
- The company reported a 6% organic revenue increase in Q4 2024, driven by a 7% rise in its core Companion Animal Group (CAG) Diagnostic recurring revenues.
- Operating profits grew 7% as reported, and 8% on a comparable basis, supported by favorable gross margin gains.
LGMK: New Products, New Distribution Channels, New Agreements
- Zacks Small-Cap Research Note for LogicMark, Inc. (LGMK)
Shionogi & Co (4507 JP): 9MFY25 Revenue Flat; Insomnia Drug Launched; NDA Submission in Japan
- Shionogi & Co (4507 JP) reported 1% YoY revenue decline during 9MFY25 as domestic sales of prescription drugs decreased 38% YoY.
- Quviviq, a DORA treatment for insomnia was launched in December 2024. Shionogi acquired exclusive distribution rights for Quviviq in Japan and it is expected to be a significant revenue contributor.
- Shionogi submitted NDA in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). Approval is expected in H1FY26.
Tsumura & Co (4540 JP): Q3 FY03/25 flash update
- Revenue reached JPY136.8bn, with a 20.6% YoY increase in domestic business and flat growth in China business.
- Operating profit rose 69.1% YoY to JPY32.4bn, driven by revenue growth and a decline in cost ratios.
- The company revised its full-year forecast, lowering revenue but raising profit forecasts due to lower expenses and yen depreciation.
Charm Care Corp (6062 JP): 1H FY06/25 flash update
- In 1H FY06/25, revenue increased by 7.9% YoY, operating profit grew 11.7% YoY, maintaining high occupancy rates.
- As of end-Q2, 104 assisted-living facilities operated with 7,086 rooms, maintaining high occupancy despite increased resident departures.
- Good Partners’ revenue and profit were strong; Charm Senior Living’s referral business contributed to occupancy growth at facilities.
DYAI: Looking Toward Product Revenues
- Dyadic has developed C1, its proprietary fungal expression system that can produce a variety of recombinant proteins.
- C1 has been commercialized in industrial applications and is in development for production of pharmaceutical grade proteins.
- C1 exhibits potential to economically produce recombinant proteins, biologic vaccines, virus like particles, antibodies, Fc-fusion, enzymes, AAVs and other biopharmaceuticals.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
